Edwards mitris resilia valve receives fda approval for mitral replacement surgeries

Irvine, calif. , march 31, 2022 /prnewswire/ -- edwards lifesciences (nyse: ew) today announced it received approval from the u.s. food and drug administration (fda) for the mitris resilia valve, a tissue valve replacement specifically designed for the heart's mitral position.

EW Ratings Summary

EW Quant Ranking